Final Phase IIa Study Results Evaluating the CXCR4 Antagonist BL-8040 in Combination with Cytarabine (Ara-C) for the Treatment of Relapsed/Refractory AML Patients

Retention of AML blasts in the bone marrow (BM), facilitated by CXCR4/CXCL12 interaction, protects AML cells from chemotherapy. BL-8040 (BKT140) is a high affinity CXCR4 inhibitor with long receptor occupancy. BL-8040's anti leukemic effect is mediated through robust leukemic blast mobilization, induction of leukemia cell differentiation and apoptosis.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Gautam Borthakur, Martin Tallman, Yishai Ofran, James Foran, Geoffrey Uy, John DiPersio, Arnon Nagler, Jacob Rowe, Margaret Showel, Jessica Altman, Amnon Peled, Michal Abraham, Yaron Pereg, Abi Vainstein, Galia Oberkovitz, Tzipi Lustig, Arnon Aharon, Carl Source Type: research